UnitedHealth Group (NYSE: UNH) has rebounded from a 52-week low of $234.60 to trade around $407 as of June 11, 2026 — yet still sits 32% below its November 2024 all-time high of $603.20. Six majorUnitedHealth Group (NYSE: UNH) has rebounded from a 52-week low of $234.60 to trade around $407 as of June 11, 2026 — yet still sits 32% below its November 2024 all-time high of $603.20. Six major
Wall Street Upgraded UNH Six Times in Two Weeks! Can UnitedHealth Stock Hit $492? UNH Price Target 2026–2030
UnitedHealth Group (NYSE: UNH) has rebounded from a 52-week low of $234.60 to trade around $407 as of June 11, 2026 — yet still sits 32% below its November 2024 all-time high of $603.20.
Six major institutions raised their UNH price target in late May through early June 2026: Bernstein set the $492 ceiling on May 27, followed by Morgan Stanley at $453, BofA at $450, and JPMorgan at $466 in the first days of June.
This article covers every key analyst target, the catalysts driving them, the risks, and the long-term UNH stock price prediction for 2030.
Key Takeaways
- As of June 11, 2026, the 12-month UNH price target consensus from 28–34 Wall Street analysts ranges from $397 to $408, with conviction-weighted targets from JPMorgan, BofA, and Morgan Stanley clustering between $450 and $466.
- Bernstein holds the highest active analyst target at $492 (Outperform, May 27), while Deutsche Bank remains the most cautious at $360 (Hold) — a $205 spread that reflects genuine institutional disagreement, not minor variance.
- UNH's Q1 2026 adjusted EPS of $7.23 beat Wall Street consensus by approximately 10%, and the Medical Care Ratio improved to 83.9% — the clearest evidence yet that the company's cost cycle is turning.
- The long-term UNH stock price prediction for 2030 spans $495–$660+ depending on three key variables: DOJ investigation outcome, pace of Medicare Advantage margin recovery, and whether Optum is eventually re-rated as a technology asset.
- Four risks can individually invalidate the bullish thesis: the DOJ antitrust investigation, the 2027 CMS coding adjustment, Medicaid funding cuts already producing membership attrition, and the Massachusetts $100M overbilling lawsuit filed May 29, 2026.
- The single most important near-term catalyst is Q2 2026 earnings on July 27 — a second consecutive Medical Care Ratio reading below 84% would validate the recovery; a reversal above 85% would likely trigger a fresh round of analyst target cuts.
UNH Price Target 2026: $492 Ceiling, $287 Floor — What 34 Analysts Are Actually Forecasting
The current UNH price target landscape is more divided than it appears at first glance.
While the headline upgrades from bulge-bracket firms grab attention, the spread between the most bearish and most bullish active targets — $287 on the low end, $492 at the top — is a $205 range that is unusually wide for a company of UNH's size and coverage depth.
That spread is not just noise; it reflects a genuine institutional disagreement about whether UNH's regulatory and operational problems are cyclical and fixable or structural and persistent.
The Full UNH Stock Price Target Table (June 2026)
The most recently filed analyst targets, as tracked by TipRanks and StockAnalysis.com, are as follows:
Institution | 12-Month Target | Rating | Date Filed |
Bernstein | $492 | Outperform | May 27, 2026 |
JPMorgan | $466 | Overweight | Jun 8, 2026 |
Mizuho | $460 | Outperform | Jun 8, 2026 |
UBS | $460 | Outperform | May 22, 2026 |
Morgan Stanley | $453 | Overweight | Jun 4, 2026 |
Bank of America | $450 | Buy (upgraded) | Jun 4, 2026 |
Truist | $440 | Buy | Jun 1, 2026 |
Barclays | $429 | — | May 26, 2026 |
Raymond James | $370 | — | Raised from $330 |
Deutsche Bank | $360 | Hold | — |
Bernstein currently holds the highest active UNH analyst price target at $492, implying roughly 21% upside from the current trading range.
JPMorgan and Mizuho, both filing on June 8, occupy the second tier at $466 and $460 respectively — with JPMorgan's Lisa Gill maintaining an Overweight rating and Mizuho citing renewed optimism around the managed care sector's re-entry setup.
At the conservative end, Deutsche Bank's Hold rating with a $360 target and Raymond James at $370 represent a meaningful minority view: acknowledge the improvement, but don't yet have enough confidence to issue a Buy.
UNH Analyst Price Target Consensus Is $403–$460
Individual firm targets tell one story; the aggregated consensus tells a slightly more measured one.
According to TradingView, drawing on input from 31 analysts, the UNH analyst price target consensus stands at $408.28, with a high estimate of $492 and a low of $287.
S&P Global Market Intelligence, tracking 28 analysts, places the consensus at $403.69, reflecting a collective "Buy" rating — implying roughly 2% upside from the $395–$407 range UNH has been trading in through early June.
ChartMill, which aggregates data from 34 Wall Street analysts, reports an average UNH target price of $397.44 — and importantly, that average has been revised upward by 5.12% in the past three months, signaling a directional shift in institutional sentiment rather than a single-event spike.
The three most recently filed ratings — Bernstein ($492), Barclays ($429), and UBS ($460) — yield a blended average of $460.33, implying approximately 20.7% upside from around that time's trading price.
The practical read: if the older, more conservative targets are weighted more heavily, the consensus sits right at $403–$408 and the stock is essentially fairly valued at current levels.
If the most recently issued targets are treated as the more accurate signal — which many professional traders do — then the actionable range is the $450–$466 cluster, suggesting 10–15% additional upside if the recovery thesis holds.
Why Wall Street Raised the UNH Target Price Six Times in Two Weeks
The wave of UNH price target upgrades in June 2026 did not emerge from nowhere.
Four distinct catalysts have converged to shift institutional sentiment from skeptical to cautiously constructive — and each one is worth understanding in detail, because each one also carries a reversal risk.
UNH Q1 2026 EPS Beat Consensus by 10% — and the Medical Care Ratio Finally Moved the Right Way
The single most important development behind the recent UNH target price upgrades was the first-quarter 2026 earnings report.
UNH reported adjusted EPS of $7.23 for Q1 2026 against a consensus estimate of $6.58 (against a consensus estimate of approximately $6.46–$6.58 depending on the data provider) — a beat of approximately 10% that caught the street off-guard given how cautiously management had been guiding.
More significant than the headline EPS number was the Medical Care Ratio (MCR) reading.
The MCR came in at 83.9% in Q1 2026, down 90 basis points from the same period in 2025 — though the company's Q1 earnings filing notes that 20 of those 90 basis points reflected a one-time reserve benefit from previously disclosed Optum Health loss contracts. Adjusting for that, the underlying improvement was approximately 70 basis points — still meaningful, but worth noting.
For context: investors had been watching UNH's MCR deteriorate through 2024 into early 2025 as a result of elevated post-pandemic utilization and Medicare Advantage rate pressure.
A second consecutive quarter below 84% would confirm that the cost cycle is genuinely turning, rather than just producing a one-quarter statistical blip.
BofA's Kevin Fischbeck stated that UNH's underlying earnings power now stands well ahead of its initial 2026 EPS guidance — a conservative baseline that current trends suggest the company will significantly outrun, with updated full-year adjusted EPS guidance now standing above $18.25.
78% of Members in 4+ Star Plans: The Medicare Advantage Rating That Changed the UNH Story
UnitedHealth's better-than-expected preliminary 2026 Medicare Advantage Star ratings — with 78% of members now enrolled in plans rated 4 stars or above — provided improved earnings visibility and alleviated investor concerns over regulatory headwinds.
This matters because CMS directly ties reimbursement bonuses to Star ratings; plans at 4+ stars receive higher per-member-per-month payments, which feeds directly into margin structure.
Following the ratings release, multiple firms raised their UNH analyst price target specifically citing the improved earnings visibility this provides into 2027.
The 4+ Star achievement also acts as a partial offset to the broader Medicare Advantage rate pressure that has been weighing on the managed care sector — it does not eliminate the risk, but it moderates it.
Avery, Optum Real, and the AI Thesis Behind Every Bullish UNH Stock Price Forecast
Morgan Stanley analyst Erin Wright explicitly flagged these AI tailwinds in her June 4 upgrade note, raising her price target to $453 from $395 while keeping an Overweight rating, and identifying the Optum platform's scale as a medium-term differentiator relative to managed care peers.
The Optum thesis is not just about cost efficiency; it is about valuation reclassification — whether the market begins to price part of UNH's business at a technology multiple rather than an insurance multiple.
A 5% Dividend Hike After 17 Consecutive Years
Following the 2026 annual shareholder meeting, UNH raised its quarterly dividend by 5% to $2.32 per share — an action management described as consistent with its long-standing commitment to annual dividend growth.
For institutional holders, a dividend increase during a period of earnings pressure is not a small signal.
It communicates that management believes the cash generation base is stable enough to sustain the payout program — and it functions as a de-facto floor for long-term valuation models that incorporate discounted cash flow.
The 17-year streak itself carries weight: breaking it would be a significantly negative event, which means the company has an incentive to protect it even under pressure.
UNH Stock Price Prediction 2030: $495 Conservative, $650 Bull Case
The long-term UNH stock price prediction for 2030 is arguably the more important question for non-traders, and it is also the more honest one to answer with a range rather than a point estimate.
The stock then experienced a dramatic decline, with the 52-week low hitting $234.60 before the June 2026 recovery brought it back toward $400.
The 2030 question is whether UNH simply re-traces its prior highs, or whether a combination of Optum monetization and earnings recovery creates the conditions for genuinely new territory above $600.
The EPS Math Behind the Long-Term UNH Price Prediction
The most defensible way to approach any long-term UNH price prediction is to anchor it in the earnings trajectory rather than model-generated extrapolations.
BofA projects 13–16% annual EPS growth for UNH once the company hits its long-term margin targets — with $26+ EPS achievable by 2028 on the low end of that range.
Working forward from that 2028 baseline: at 14% compound annual growth, 2030 EPS would approach $33–$34.
Applying a conservative 15x price-to-earnings multiple — significantly below UNH's historical peak of over 25x, but reflecting a persistent regulatory discount — yields a 2030 price target of approximately $495–$510.
At a 18x multiple (a more normalized managed care valuation), the same EPS trajectory implies $594–$612 — effectively reclaiming the all-time high.
At 20x, which would require genuine Optum re-rating, the arithmetic pushes above $660.
None of these scenarios are guaranteed; all three require the company to execute on margin recovery without a material regulatory disruption over a four-year window.
Optum as a Standalone Value Driver in the 2030 Thesis
The structural argument for any bull case UNH stock price forecast for 2030 rests not just on insurance earnings recovery, but on how the market chooses to value Optum.
Optum Health (care delivery), Optum Insight (data analytics and healthcare IT), and Optum Rx (pharmacy benefit management) together constitute a vertically integrated platform that has few direct comparables at scale.
If the market were to assign Optum a technology-sector valuation multiple rather than bundling it with the insurance business, sum-of-the-parts analysis would suggest meaningful additional value per share — a re-rating catalyst that does not depend on insurance earnings recovery alone.
That re-rating, if it materialized, would add a non-earnings-growth pathway to higher stock prices — effectively creating a catalyst that does not depend on the insurance business continuing to improve.
Bear, Base, and Bull: Three Scenarios for UNH by 2030
The bear case assumes DOJ investigation escalates to forced divestitures of key Optum assets, Medicaid headwinds persist beyond 2027, and CMS enacts another round of Medicare Advantage rate compression — under this scenario, UNH is likely still trading between $350 and $420 by 2030, representing roughly flat returns from current levels.
The base case assumes regulatory risk partially resolves, the MCR stabilizes below 85%, and EPS compounds at 10–12% annually from the 2026 floor — placing UNH in the $520–$580 range by 2030 and representing a partial but not complete recovery to prior all-time highs.
The bull case requires three things to break right simultaneously: DOJ investigation concludes without structural remedies, Optum AI platforms begin contributing meaningfully to margins, and EPS growth re-accelerates toward the 15% trajectory BofA has modeled — under which scenario UNH trades above $650 by 2030, setting a new all-time high.
Of the three scenarios, the base case is the most statistically probable given what institutional analysts are currently projecting; the bull case is plausible but requires more luck than the upgrade wave currently implies.
Four Risks That Could Send the UNH Analyst Price Target From $492 Down to $287
Every UNH price target upgrade issued in June 2026 was filed with some version of the same caveat: the bull case is real, but the risk landscape remains unusually complex for a company of this size.
Traders who treat the $450–$466 cluster of targets as a firm destination rather than a conditional projection are likely underestimating the number of variables that could turn against the thesis before Q2 earnings even report.
DOJ Antitrust Investigation: The Binary Risk That Overhangs Every Target
The Department of Justice antitrust investigation into UnitedHealth Group remains the largest single binary risk embedded in the current stock.
Any escalation — particularly one involving forced divestiture of Optum assets — would not merely pressure the stock; it would invalidate the core investment thesis that underpins every bullish target currently on the board.
UNH stock has proven sensitive to regulatory headlines — major DOJ-related developments are capable of generating outsized single-session price moves that stop-losses alone cannot fully manage.
Major investment banks have not published base-case scenarios that explicitly model forced divestiture of Optum assets — meaning the price targets on the board represent a world where DOJ risk is contained, not eliminated.
CMS Rate Uncertainty and the 2027 Coding Adjustment
BofA analyst Kevin Fischbeck noted that until the firm had more clarity on the potential for a 2027 Medicare Advantage coding adjustment, it would remain cautious — and that significant upside is contingent on rates not being a headwind.
CMS coding adjustments affect how Medicare Advantage plans can classify member risk scores, which directly affects how much reimbursement UNH receives per enrolled member.
A negative 2027 adjustment would compress per-member revenue at exactly the wrong moment — when the company is trying to demonstrate sustained margin recovery.
The CMS preliminary 2028 Star Ratings, expected in late 2026, will function as a leading indicator for this dynamic and represent a discrete event that could either accelerate or derail the current upgrade cycle.
Medicaid Headwinds and the Community & State Drag
Legislative changes enacted in 2025 led to major funding cuts in Medicaid for 2026, and UNH management has already flagged expectations for membership attrition and negative margins within the Community & State segment throughout the year.
For a company of UNH's enrollment scale, even a modest per-member margin deterioration in Medicaid translates directly into hundreds of millions of dollars of operating income erosion at the segment level.
Raymond James and Deutsche Bank — the two most cautious voices among major coverage banks — have both maintained Hold-equivalent ratings, with analysts at each firm pointing to ongoing regulatory uncertainty and Medicaid headwinds as factors limiting their conviction.
Legal Exposure and the Institutional Trust Deficit
In May 2026, the state of Massachusetts filed a lawsuit against a UnitedHealth unit, alleging at least $100 million in fraudulent overbilling of the MassHealth Medicaid program.
The case raises an uncomfortable question about whether similar exposure exists in other state Medicaid programs — and legal risk of this type compounds rather than diminishes when a company is already under DOJ scrutiny.
Perhaps more importantly, UNH's implied 2026 EPS guidance of approximately $17 is less than half of the $35 per share that investors were modeling just twelve months ago.
Rebuilding institutional trust after a guidance reset of that magnitude typically requires more than a single earnings beat — and that dynamic is reflected in why several major banks are still holding their cautious ratings despite acknowledging the Q1 improvement.
Traders should treat the current upgrade wave not as evidence that trust has been fully restored, but as an early signal that the credibility restoration process has begun.
How to Read the UNH Analyst Price Target Consensus as a Trader
Understanding what a price target is — and more importantly, what it is not — is essential before acting on any of the numbers presented above.
A 12-month analyst price target is a conditional forecast based on assumptions about earnings, multiple expansion, and operating environment that are updated quarterly at best and can be invalidated by a single news event.
The UNH target price table should be read as a map of institutional conviction, not as a guarantee of future stock price.
Understanding the $287–$492 Spread in UNH Target Price
The current analyst range for UNH runs from $287 on the low end to $492 on the high end — a $205 spread that is unusually wide for a large-cap stock with the depth of coverage UNH receives.
A narrow analyst spread signals consensus; a wide spread signals unresolved uncertainty about structural factors.
In UNH's case, the spread reflects the fact that analysts genuinely cannot agree on how to model the DOJ outcome, the CMS 2027 dynamic, and the pace of Medicaid recovery — all of which can swing the fundamental value of the company significantly in either direction.
For traders: the most actionable read is the cluster between $440 and $466, where BofA, Morgan Stanley, JPMorgan, and Mizuho have all recently settled.
A sustained break above $450 on improving MCR and volume confirmation would suggest the bull-case tier of targets is gaining traction; a failure at $420–$430 resistance and subsequent breakdown would suggest the upgrade wave was premature.
Q2 2026 Earnings Date: The Next UNH Stock Price Forecast Catalyst
UNH is expected to report Q2 2026 earnings on July 27, 2026, before the market open, with analyst consensus calling for EPS of approximately $4.88 on revenue of around $110.76 billion.
The Medical Care Ratio reading will be the single most scrutinized figure in that report.
A second consecutive quarter at or below 84% would validate the BofA and Morgan Stanley recovery theses and likely trigger another round of target increases from firms still sitting at $360–$395.
A reversal back above 85% would almost certainly trigger target cuts from the firms that most recently upgraded — and given that UNH is trading near consensus target, there is limited technical cushion to absorb a negative surprise.
The Medicaid membership number will be the secondary focal point: how much attrition actually materialized in Q2 will determine whether the Community & State drag is modeled as a 2026-only event or a multi-year headwind.
UNH Dividend Ex-Date and the Institutional Positioning Context
UNH shares go ex-dividend on June 15, 2026, for the quarterly payment of $2.32 per share.
For institutional accounts with dividend capture strategies, the ex-date creates a short-term positioning consideration in the week of June 9–13.
The more structurally significant observation is that UNH is now sustaining its dividend program through a multi-year turnaround — which reduces the probability of a forced dividend cut and maintains its attractiveness as a core healthcare holding for income-oriented institutional portfolios.
FAQ
Q: What is the UNH price target for 2026?
The 12-month UNH price target consensus from 28–34 Wall Street analysts currently ranges from $397 to $408 as an average, with the most recent high-conviction targets from JPMorgan ($466) and Bernstein ($492) pointing to a higher ceiling if the margin recovery continues.
Q: What is the UNH analyst price target consensus right now?
According to S&P Global Market Intelligence, tracking 28 analysts, the UNH analyst price target consensus is $403.69, with a collective "Buy" rating as of June 2026.
Q: Who has the highest UNH stock price target among analysts?
Bernstein currently holds the highest active UNH stock price target at $492, with an Outperform rating filed on May 27, 2026, representing approximately 28.8% implied upside at the time of issuance.
Q: What is the UNH stock price prediction for 2030?
Based on BofA's 13–16% annual EPS growth model and a conservative 15–18x forward P/E multiple applied to projected 2030 EPS of approximately $33–$34, the base-case 2030 price range works out to roughly $495–$612, with the bull case above $650 contingent on DOJ resolution and Optum re-rating.
Q: Is UNH a buy according to Wall Street analysts right now?
Of 34 analysts tracked by ChartMill, 78% hold a Buy-equivalent rating on UNH as of June 2026, though the stock is currently trading near the broader consensus average of approximately $397–$408.
Q: What is the UNH stock price prediction for 2026 beyond the 12-month target?
The UNH stock price forecast for the remainder of 2026 is most directly tied to Q2 earnings on July 27 and the CMS preliminary 2028 Star Ratings release expected in late 2026 — two discrete events that can shift analyst price targets materially in either direction.
Q: What is the UNH price target consensus from the most recently updated analysts?
The three most recently filed ratings from Bernstein, Barclays, and UBS yield a blended average UNH price target of $460.33, implying approximately 20.7% upside — a materially higher implied return than the broader consensus of $397–$408.
Q: What is the UNH share price forecast if DOJ risk clears?
Most analysts project the bull-case target of $466–$492 becomes the operative range if DOJ uncertainty dissipates — JPMorgan at $466 and Bernstein at $492 are both explicitly positioned around a scenario where regulatory risk normalizes and MCR continues to improve.
Conclusion
The 12-month UNH analyst price target consensus sits at $397–$408, with conviction-weighted targets from JPMorgan, BofA, and Morgan Stanley clustering at $450–$466 — implying 10–15% upside if Q2 2026 earnings on July 27 confirm a second consecutive MCR below 84%.
For 2030, the base case puts UNH at $520–$580; the bull case above $650 requires DOJ resolution and Optum re-rating to materialize.
Traders seeking exposure can access UNH through MEXC's tokenized stock platform.
Market Opportunity
4 Price(4)
$0.008481
$0.008481$0.008481
USD
4 (4) Live Price Chart
This article is provided by Marcus O'Brien for informational purposes only and does not constitute financial or investment advice. Cryptocurrency markets involve significant risk. Please conduct independent research or consult a qualified professional before making any investment decisions. The views expressed do not necessarily represent those of MEXC or its affiliates.
Popular Articles
View More
Venezuela Bitcoin Holdings: Official Numbers, Shadow Reserve, and the Full Story
Venezuela sits at the center of one of the strangest Bitcoin stories on earth. The country's people use crypto to buy groceries, pay rent, and send money home — while its government may secretly hold
SMCI Crashed 28% on $39 Billion in AI Orders. But Analyst Price Targets Tell a Different Story.
Super Micro Computer (NASDAQ: SMCI) is sitting at an unusual crossroads right now. The company just disclosed $39 billion in new AI server orders from more than 20 customers, one of the largest
Will IONQ Stock Reach $100 Before 2030? Every Analyst Price Target, the Disagreement, and the Long-Term Case
IonQ (NYSE: IONQ) has become one of the most actively tracked quantum computing stocks on Wall Street, and one of the most argued-about. After reporting 755% year-over-year revenue growth in Q1 2026,
TGT Stock Just Beat Earnings by 17%! Will TGT Stock Reach $160? What 38 Analysts Say About the Target Price Target
Target Corporation (NYSE: TGT) spent the better part of two years testing long-term investors' patience. The stock fell to a 52-week low of $83.44, weighed down by declining comparable sales, a CEO
Hot Crypto Updates
View More
UK FCA Proposes Limited Crypto Exposure for Retail Investment Funds: Here's What You Need to Know
1.Introduction The United Kingdom financial regulator is considering a significant policy shift that could expand access to cryptocurrency-linked investments for everyday investors. The Financial
ZEC Plunges on Infinite Mint Fears: Analyzing the Market Fallout of the Orchard Bug
Overview Zcash (ZEC) lost roughly half its value in 48 hours in early June 2026, falling from a June 4 peak near $624 to about $309 on June 5 after Shielded Labs disclosed a critical soundness flaw
SpaceX Rideshare: The Cheapest Ticket to Orbit for Small Satellites
SpaceX's Transporter, Bandwagon, and Twilight rideshare programs offer small satellite operators the lowest-cost path to orbit. Here's how each mission series works, what it costs in 2026, and how to
Trending News
View More
Cecabank Brings MiCA-Regulated Crypto Custody to Spanish Banks
TLDR: Cecabank’s MiCA-regulated crypto custody platform is now live for key Spanish financial firms today. Renta 4 Banco is an early firm to use Cecabank’s new
Ozak AI Listing Date: CEO AI-Bitcoin Vision Revealed Before OZ TGE
The presale is basically done. 99.69% sold, $7.4 million raised, and the dashboard has stopped showing a countdown. It now says two words: Next Phase: Listing.But
Related Articles
View More
DJT Down 63% From Its Peak, Will It Recover to $21 Again? DJT Stock Price Prediction for 2026 and 2030
There is no other stock quite like DJT, and that is not a compliment.Trump Media & Technology Group Corp. (NASDAQ: DJT) operates the Truth Social social media platform, the Truth+ streaming service, a
SMCI Crashed 28% on $39 Billion in AI Orders. But Analyst Price Targets Tell a Different Story.
Super Micro Computer (NASDAQ: SMCI) is sitting at an unusual crossroads right now.The company just disclosed $39 billion in new AI server orders from more than 20 customers, one of the largest backlog
Elon Musk & SpaceX: His Core Role, Ownership Stake & Key Strategic Decisions
The corporate trajectory of SpaceX is inextricably linked with its founder, Elon Musk. It sparks widespread public curiosity about his actual management authority, personal net worth, and multi-firm o
